Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML

被引：4
|
作者：
不详
机构：
来源：
ONCOLOGIST | 2021年 / 26卷
关键词：
D O I：
10.1002/onco.13652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
New data from the phase III LACEWING trial support the safety and feasibility of combining gilteritinib with azacitidine in patients with newly diagnosed FLT3-mutated acute myeloid leukemia who are not eligible for induction therapy, suggesting an important new treatment approach for these patients.
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 50 条
  • [1] Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
    Short, Nicholas J.
    Daver, Naval
    Dinardo, Courtney D.
    Kadia, Tapan
    Nasr, Lewis F.
    Macaron, Walid
    Yilmaz, Musa
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Chien, Kelly S.
    Jabbour, Elias
    Nasnas, Cedric
    Huang, Xuelin
    Qiao, Wei
    Matthews, Jairo
    Stojanik, Christopher J.
    Patel, Keyur P.
    Abramova, Regina
    Thankachan, Jennifer
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1499 - 1508
  • [2] Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Erba, H. P.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W-C
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S-S
    Lee, J-H
    Pardee, T.
    Fathi, A. T.
    Liu, C.
    Hasabou, N.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18): : 1728 - 1740
  • [3] Safety and efficacy of midostaurin in patients with newly diagnosed FLT3-mutated AML
    Wang, P-N.
    Leung, A. Y. H.
    Jang, J. H.
    Voloshin, S.
    O'Sullivan-Djentuh, L.
    Suzuki, K.
    Ifrah, S.
    Le Gouadec, G.
    Kakizume, T.
    Kitagawa, H.
    Malek, K.
    Miyazaki, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 92 - 93
  • [4] Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML
    Wang, Eunice S.
    Goldberg, Aaron D.
    Tallman, Martin
    Walter, Roland B.
    Karanes, Chatchada
    Sandhu, Karamjeet
    Vigil, Carlos E.
    Collins, Robert
    Jain, Vinay
    Stone, Richard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (15) : 1776 - 1787
  • [5] Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
    Wang, Eunice S.
    Montesinos, Pau
    Minden, Mark D.
    Lee, Je-Hwan
    Heuser, Michael
    Naoe, Tomoki
    Chou, Wen-Chien
    Laribi, Kamel
    Esteve, Jordi
    Altman, Jessica K.
    Havelange, Violaine
    Watson, Anne-Marie
    Gambacorti-Passerini, Carlo
    Patkowska, Elzbieta
    Liu, Shufang
    Wu, Ruishan
    Philipose, Nisha
    Hill, Jason E.
    Gill, Stanley C.
    Rich, Elizabeth Shima
    Tiu, Ramon, V
    BLOOD, 2022, 140 (17) : 1845 - 1857
  • [6] Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
    Wang, Eunice S.
    Montesinos, Pau
    Minden, Mark D.
    Lee, Je-Hwan
    Heuser, Michael
    Naoe, Tomoki
    Chou, Wen-Chien
    Laribi, Kamel
    Esteve, Jordi
    Altman, Jessica K.
    Havelange, Violaine
    Watson, Anne-Marie
    Patkowska, Elzbieta
    Liu, Shufang
    Wu, Ruishan
    Philipose, Nisha
    Hill, Jason E.
    Gill, Stanley
    Rich, Elizabeth Shima
    Tiu, Ramon V.
    BLOOD, 2021, 138
  • [7] BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
    Buelow, Daelynn R.
    Bhatnagar, Bhavana
    Orwick, Shelley J.
    Jeon, Jae Yoon
    Eisenmann, Eric D.
    Stromatt, Jack C.
    Pabla, Navjot Singh
    Blachly, James S.
    Baker, Sharyn D.
    Blaser, Bradley W.
    BLOOD ADVANCES, 2022, 6 (17) : 5049 - 5060
  • [8] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary
    Bradley, Terrence
    Tiu, Ramon, V
    Naqvi, Kiran
    Dail, Monique
    Brackman, Deanna
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
  • [9] High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3-Mutated AML
    Buelow, Daelynn R.
    Bhatnagar, Bhavana
    Jeon, Jae Yoon
    Thomas, Megan Zavorka
    Eisenmann, Eric
    Stromatt, Jack
    Orwick, Shelley
    Pabla, Navjot
    Blachly, James S.
    Baker, Sharyn
    Blaser, Bradley W.
    BLOOD, 2021, 138
  • [10] Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
    McCall, David
    Roth, Michael
    Mahadeo, Kris M.
    Toepfer, Laurie
    Nunez, Cesar
    Short, Nicholas J.
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney
    Yi, Joanna S.
    Cuglievan, Branko
    BLOOD ADVANCES, 2021, 5 (23) : 5215 - 5219
12345